3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Meningioma
1
Malignant Female Reproductive System Neoplasm
1
Hemangiosarcoma
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Disease Progression
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Bevacizumab
2
temsirolimus
1
neratinib
1
brigatinib
1
Valproic Acid
1
Sirolimus
1
Immunoglobulin G
1
Disulfides
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurofibromatosis 2
×
neratinib
×
90 days
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled